Associated Papers
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
Zhang Q et al.
Journal of Medicinal Chemistry, 2025
Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.
Choi YJ et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Chu QS
Therapeutic Advances in Medical Oncology, 2020
Select a paper to view details